Coca-Cola (KO) and Starbucks (SBUX) are among the most well-known brands in the world. The old winning recipe for refreshment companies was to assemble brands, create flagship products and hold up for the cash registers to ring.
Reinvented
Coca-Cola's numbers speak for themselves, with Coca-Cola's piece of the overall industry of U.S. carbonated soft drinks (CSDs) having stayed stable for the past few decades. Yet even a titan like Coca-Cola was unavoidably influenced by the pattern of consumers moving far from sodas because of increased health consciousness.
Coca-Cola has taken a shot at staying applicable with consumers. One such activity is the dispatch of its Freestyle machine, which dispenses 146 remarkable flavors. This works because it's confronted with another era of consumers.
Coca-Cola also took item customization and individualization to an entire new level with its 2013 U.K. "Share a Coke" fight, where it supplanted the names of Coca-Cola brands with 150 mainstream English names. This set consumers on the chase for Cokes conveying their names. A similar battle in Australia in 2011 resulted in 7% development in grown-up consumption.
Hot Value Companies To Watch In Right Now: Lincoln Educational Services Corporation(LINC)
Lincoln Educational Services Corporation provides post-secondary education services in the United States. The company offers degree and diploma programs for recent high school graduates and working adults in the areas of studies, such as health science, automotive technology, skilled trades, business and information technology, and hospitality services. As of December 31, 2011, it had 19,204 enrolled students. The company operates 46 schools in 17 states under Lincoln Technical Institute, Lincoln College of Technology, Lincoln College of New England, Nashville Auto-Diesel College, and Euphoria Institute of Beauty Arts and Sciences brand names, as well as offers online programs. Lincoln Educational Services Corporation was founded in 1946 and is headquartered in West Orange, New Jersey.
Advisors' Opinion:- [By Jon C. Ogg]
Teradyne will replace Scholastic Corp. (NASDAQ: SCHL) in the S&P MidCap 400, and Scholastic will replace Lincoln Education Services Corp. (NASDAQ: LINC) in the S&P SmallCap 600. Lincoln Education Services currently ranks 600th in the S&P SmallCap 600 and is no longer representative of the small cap market space.
Top 10 Healthcare Technology Companies To Watch In Right Now: Attitude Drinks Inc (ATTD)
Attitude Drinks Incorporated (Attitude), incorporated on May 10, 1988, is a brand-development company. The Company focuses on the non-alcoholic single serving beverage business, developing and marketing of milk based products in two segments: sports recovery and functional dairy. The Company does not directly manufacture its products but instead outsources the manufacturing process to third party packers.
Attitude has developed its second product, which is branded as Phase III Recovery is a milk-based protein drink which is available in chocolate and vanilla flavors. The Company�� co-packer for its dairy based product is O-AT-KA Milk Products Cooperative, Inc. in Batavia, New York. This product contains 35 grams of protein that are inherent in filtered milk. The product is packaged as a retort-processed shelf stable dairy-based 100% milk-based sports recovery drink in both chocolate and vanilla flavors.
The Company competes with The Coca-Cola Company and Pepsico Inc.
Advisors' Opinion:- [By Peter Graham]
Small cap stocks Attitude Drinks Inc (OTCMKTS: ATTD), Axiologix, Inc (OTCMKTS: AXLX) and Unisource Corporation (OTCMKTS: USRC) have all been getting some attention lately in investment emails or investor alerts thanks in part to paid promotions. And while there is nothing wrong with properly disclosed paid promotions or investor relations activity, such activity can backfire on unwary investors or traders. With that in mind, here is a closer look at all three small cap stocks to help you decide whether they are truly hot or not:
Top 10 Healthcare Technology Companies To Watch In Right Now: iShares MSCI Japan ETF (EWJ)
iShares MSCI Japan Index Fund (the Fund) seeks to provide investment results that correspond generally to the price and yield performance of publicly traded securities in the aggregate in the Japanese market, as measured by the MSCI Japan Index (the Index). The Index seeks to measure the performance of the Japanese equity market. The Index is a capitalization-weighted index that aims to capture 85% of the (publicly available) total market capitalization. Component companies are adjusted for available float and must meet objective criteria for inclusion in the Index. The Index is reviewed quarterly.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. iShares MSCI Japan Index Fund's investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Richard Shaw]
Securities Mentioned: S&P 500 (SPY), Europe (VGK), Japan (EWJ), China (GXC).
Disclosure: QVM has positions in SPY and VGK as of the creation date of this article (July 11, 2013). We certify that except as cited herein, this is our work product. We received no compensation or other inducement from any party to produce this article, and are not compensated by Seeking Alpha in any way relating to this article.
- [By Matthew McCall]
iShares MSCI Japan ETF (NYSE: EWJ)
The first country to open for the week after the news out of Ukraine hit the wires was Japan, and it was an ugly open. The major stock indices fell by over two percent before they were able to rebound and the Nikkei finished the first day of the week lower by 1.3 percent. The Japanese Yen was down 0.5 percent versus the U.S. Dollar, which is good news for Japanese exporters.
- [By Mark Hulbert]
The ETFs linked to these respective regions that Mr. Nadig�� firm favors are the iShares MSCI Japan fund (EWJ) �, with a 0.53% expense ratio; the iShares MSCI EMU Index fund (EZJ) �, also with a 0.53% expense ratio; and the iShares Core MSCI Emerging Markets fund (IEMG) �, with a 0.18% expense ratio.
Top 10 Healthcare Technology Companies To Watch In Right Now: KCG Holdings Inc (KCG)
KCG Holdings, Inc., incorporated on December 26, 2012, is an independent securities firm. The Company offers investors a range of services designed to address trading needs across asset classes, product types and time zones. It has three operating segments: Market Making, Global Execution Services, and Corporate and Other. On July 1, 2013, the Company announced the completion of the merger whereby Knight Capital Group, Inc. (Knight) and GETCO Holding Company, LLC (GETCO) were combined as part of KCG Holdings, Inc., a new holding company.
Market Making
The Company�� Market Making segment principally consists of market making in global equities and listed domestic options. As a market maker, the Company commits capital for trade executions by offering to buy securities from, or sell securities to, institutions and broker-dealers. The Market Making segment primarily includes client, and to a lesser extent, non-client market making activities in which the Company operates as a market maker in equity securities quoted and traded on the Nasdaq Stock Market; the over-the-counter (OTC) market for New York Stock Exchange (NYSE), NYSE Amex Equities (NYSE Amex), NYSE Arca listed securities, and several European exchanges. As a complement to electronic market making, the Company�� cash trading business handles specialized orders and also transacts on the OTC Bulletin Board, marketplaces operated by the OTC Markets Group Inc. and the Alternative Investment Market (AIM) of the London Stock Exchange. The segment also provides trade executions as an equities Designated Market Maker (DMM) on the NYSE and NYSE Amex. The Market Making segment also includes the Company�� option market making business which trades on all domestic electronic exchanges.
Global Execution Services
The Company�� Global Execution Services segment offers access through its electronic agency-based platforms to markets and self-directed trading in equities, options, fixed income, foreign ! exchange and futures. The Global Execution Services segment generally does not act as a principal to transactions that are executed within this segment however, it will commit capital on behalf of clients, as needed, and generally earns commissions for acting as agent between the principals to the trade. Global Execution Services includes equity sales and trading (including exchange traded funds (ETFs)), reverse mortgage origination and securitization and asset management. This segment also facilitates client orders through program, block, and riskless principal trades and provides capital markets services, including equity offerings, as well as private placements. The Global Execution Services segment also includes the futures commission merchant (FCM) business, which consists of certain assets and liabilities that the Company acquired or assumed from the futures division of Penson Financial Services, Inc.
Corporate and Other
The Corporate and Other segment invests in strategic financial services-oriented opportunities, allocates, deploys and monitors all capital, and maintains corporate overhead expenses and all other income and expenses that are not attributable to the other segments. The Corporate and Other segment houses functions that support the Company�� other segments, such as self-clearing services, including stock lending activities.
The Company competes with BGC Partners (BGCP), Chicago Board Options Exchange (CBOE), CME (CME), GFI Group Inc. (GFIG), ICE (ICE), ITG (ITG), Forex Capital Markets (FXCM), MarketAxess (MKTX), National Association of Securities Dealers Automated Quotations (NASDAQ), and NYSE.
Advisors' Opinion:- [By Sam Mamudi]
Knight, which in July joined with Getco LLC to form KCG Holdings Inc. (KCG) after losing more than $460 million because of the error, agreed to settle charges stemming from mistakes made on Aug. 1, 2012, according to a statement today from the U.S. Securities and Exchange Commission. The regulator said Knight violated the SEC�� market access rule, instituted in 2010 to prevent these kinds of trading missteps.
Top 10 Healthcare Technology Companies To Watch In Right Now: Novartis AG (NVS)
Novartis AG, incorporated on February 29, 1996, provides healthcare solutions. The Company is a multinational group of companies specializing in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. Its portfolio includes medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. The Company has five segments: Pharmaceuticals, which include patent-protected prescription medicines; Alcon, which include surgical, ophthalmic pharmaceutical and vision care products; Sandoz, which include generic pharmaceuticals; vaccines and diagnostics, which include human vaccines and blood-testing diagnostics, and consumer health, which include over-the-counter medicines (OTC) and Animal Health. On April 8, 2011, the Company acquired the remaining non-controlling interest in Alcon, Inc. In December 2013, Alliance Pharma plc announced that its wholly owned subsidiary, Alliance Pharmaceuticals Limited, acquired all the United Kingdom and Republic of Ireland (ROI) rights to Lypsyl from Novartis AG.
In April 2011, Novartis sells global rights to Elidel, a medicine to treat atopic dermatitis to Meda. In March 2011, Novartis completes acquisition of majority stake in Zhejiang Tianyuan vaccines company in China. In March 2011, the Company acquired Genoptix, Inc. In October 2011, Novartis discontinues development of AGO178 for depressive disorder. In December 2011, the Company discontinues development of PRT128 for acute coronary syndrome and chronic coronary heart disease, and SMC021 for osteoporosis and osteoarthritis. In April 2011, Alcon's portfolio of generic ophthalmic medicines sold through its Falcon business unit primarily in the United States.
Pharmaceuticals Division
The Company�� Pharmaceuticals Division researches, develops, manufactures, distributes and sells patented prescription medicines in the therapeutic areas, such as Oncol! ogy; Primary Care, consisting of Primary Care medicines and Established Medicines, and Specialty Care, consisting of Ophthalmology, Neuroscience, Integrated Hospital Care, and Critical Care medicines. The Pharmaceuticals Division is organized into global business franchises responsible for the commercialization of various products, as well as Novartis Oncology, a business unit responsible for the global development and commercialization of oncology products, and Novartis Molecular Diagnostics, a business responsible for the development and commercialization of diagnostic tests and services related to its pharmaceuticals portfolio and therapeutic areas.
The Company�� Oncology products include Afinitor/Votubia, Exjade, Sandostatin SC/Sandostatin LAR , Femara , Zometa, Tasigna and Gleevec/Glivec. Gleevec/Glivec, which is a signal transduction inhibitor approved to treat patients with certain forms of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). Tasigna is a signal transduction inhibitor of the tyrosine kinase activity of Bcr-Abl, KIT+ and the PDGF-receptor. Zometa is a treatment to reduce or delay skeletal-related events (SREs), including pathologic fracture, spinal cord compression, and/or requirement of radiation therapy or surgery to bone, in patients with bone metastases (cancer that has spread to the bones) from solid tumors and multiple myeloma. Femara is a once-daily oral aromatase inhibitor for the treatment of early stage or advanced breast cancer in postmenopausal women. Sandostatin SC/Sandostatin LAR is indicated for the treatment of patients with acromegaly, a chronic disease caused by over-secretion of pituitary growth hormone in adults. Sandostatin is also indicated for the treatment of patients with certain symptoms associated with carcinoid tumors and other types of gastrointestinal and pancreatic neuroendocrine tumors. Exjade is an oral iron chelator approved for the treatment of chronic iron overload due to blood transfusions in patients over ! two years! of age who have a range of underlying anemias. Patients with congenital and acquired chronic anemia, such as thalassemia, sickle cell disease and myelodysplastic syndromes, require transfusions, which puts them at risk of iron overload. Afinitor/Votubia is an oral inhibitor of the mTOR pathway.
The Company�� Primary Care products include Arcapta Neohaler/Onbrez Breezhaler, Diovan, Exforge, Tekturna/Rasilez, Galvus, Reclast/Aclasta, Voltaren/Cataflam, Ritalin, Ritalin LA, Focalin and Focalin XR. Its Specialty Care products include Lucentis, Gilenya, Exelon, Extavia and Comtan, and Stalevo. Its Integrated Hospital Care include Zortress/Certican, Ilaris, Neoral and Myfortic.The Company�� Critical Care products include Xolair and Tobi Podhaler. As of December 31, 2011, the products under development includes ACZ885, which is being investigated for the secondary prevention of cardiovascular events and for the treatment of Diabetes Mellitus; AEB071 (sotrastaurin) is a low molecular weight, selective inhibitor of protein kinase-C (PKC); AFQ056 (mavoglurant) is a metabotropic glutamate receptor 5 (mGluR5) antagonist in Phase II development for the treatment of Parkinson's disease levodopa-induced dyskinesia; AIN457 (secukinumab) is a human monoclonal antibody neutralizing interleukin-17A, a key pro-inflammatory cytokine expressed by TH17 cells and other types of white blood cells; BAF312 is an oral, second-generation sphingosine 1-phosphate receptor modulator in Phase II development for relapsing-remitting multiple sclerosis; DEB025 (alisporivir) is a cyclophilin inhibitor for the treatment of Hepatitis C virus infection (HCV); Gileny a line treatment for relapsing forms of MS; Exjade (deferasirox) is an oral iron chelator in development for use in patients with non-transfusion-dependent thalassemia (NTDT); INC424 (ruxolitinib) is an investigational Janus kinase (JAK) inhibitor, and Zortress/Certican (everolimus) is an mTOR inhibitor with immune/non-immune cell proliferation inhibition being d! eveloped ! for prevention of solid organ transplant rejection.
Alcon Division
The Company�� Alcon Division discovers, develops, manufactures, distributes and sells eye care products. Alcon is engaged in eye care with product offerings in Surgical, Ophthalmic Pharmaceuticals and Vision Care. In Surgical, Alcon develops, manufactures, distributes and sells ophthalmic surgical equipment, instruments, disposable products and intraocular lenses. In Pharmaceutical, Alcon discovers, develops, manufactures, distributes and sells medicines to treat chronic and acute diseases of the eye, as well as over-the-counter medicines for the eye. In Vision Care, Alcon develops, manufactures, distributes and sells contact lenses and lens care products.
Alcon's Surgical portfolio includes the Infiniti vision system for cataract procedures, the Constellation vision system for retinal operations, and the AcrySof family of intraocular lenses (IOLs), including the AcrySof IQ, AcrySof IQ ReSTOR, AcrySof IQ Toric and AcrySof IQ ReSTOR Toric IOLs. During the year ended December 31, 2011, its Alcon Division launched the LenSx femtosecond laser, a technology in cataract surgery, which increases the precision and reproductibility for corneal incisions, capsulorhexis and lens fragmentation steps of the procedure. In addition, Alcon provides advanced viscoelastics, surgical solutions, surgical packs and other disposable products for cataract and vitreoretinal surgery.
Alcon Division's Ophthalmic Pharmaceuticals business combines Alcon's range of pharmaceuticals with selected ophthalmic products (excluding Lucentis) previously marketed by the Novartis Pharmaceuticals Division. The products treat chronic and acute diseases of the eye including glaucoma and allergies, as well as anti-infective/anti-inflammatory and dry eye treatments. our Alcon Division's Ophthalmic Pharmaceuticals portfolio include Travatan Z solution and DuoTrav solution for the treatment of elevated intraocular pressure associ! ated with! glaucoma; Vigamox solution for bacterial conjunctivitis; Pataday solution for ocular itching associated with allergic conjunctivitis; and Nevanac suspension for eye inflammation following cataract surgery. Alcon launched a number of products during 2011, including Dailies Total 1 lenses, Opti-Free EverMoist Multi Purpose Disinfecting Solution, LenSx laser, AcrySof IQ ReSTOR Toric lens, AcrySof IQ Toric T6-T9 lens, Travatan BAK-free solution, DuoTrav BAK-free solution, Moxeza solution and Systane Balance eye drops.
Sandoz Division
The Company�� Sandoz Division is a global generic pharmaceuticals company that develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical and biotechnological active substances, which are not protected by valid and enforceable third-party patents. The Sandoz Division has activities in Retail Generics, Anti-Infectives, and Biopharmaceuticals and Oncology Injectables. In Retail Generics, Sandoz develops, manufactures and markets active ingredients and finished dosage forms of pharmaceuticals, as well as supplying active ingredients to third parties. In Anti-Infectives, Sandoz develops and manufactures active pharmaceutical ingredients and intermediates, mainly antibiotics, for internal use by retail generics and for sale to third-party customers. In Biopharmaceuticals, Sandoz develops, manufactures and markets protein- or other biotechnology-based products (biosimilars or follow-on biologics) and sells biotech manufacturing services to other companies.
In Oncology Injectables, Sandoz develops, manufactures and markets primarily cytotoxic products for the hospital market. During 2011, the Company launched generic docetaxel (Taxotere), higher-strength generic amlodipine-benazepril (Lotrel), generic meropenem (Merem) injection, and the formation of a women's health portfolio with generic Seasonale, Nordette, Yaz and Yasmin. The product launched in various European countries included generic docetaxel, ge! neric ana! strazole (Arimidex), and valsartan/covalsartan (an early entry generic version of Novartis Pharmaceuticals' Diovan/Co-Diovan).
Vaccines and Diagnostics Division
The Company�� Vaccines and Diagnostics Division researches, develops, manufactures, distributes and sells preventive vaccines and diagnostic tools. Novartis Vaccines is a global developer and manufacturer of human vaccines. Novartis Diagnostics is a blood testing and molecular diagnostics business dedicated to preventing the spread of infectious diseases through blood-screening tools that protect the world's blood supply. Novartis Vaccines' products include influenza, meningococcal, pediatric, adult and travel vaccines.
The Company�� influenza vaccines include Agrippal, Fluad, Fluvirin and Optaflu. Its Meningococcal Vaccines includes Menjugate and Menveo. Its travel vaccines include Encepur Children, Encepur Adults, Ixiaro and Rabipur/Rabavert. Its Pediatric Vaccines include Polioral and Quinvaxem.
Consumer Health
Consumer Health consists of two Divisions: OTC (over-the-counter medicines) and Animal Health. Each has its own research, development, manufacturing, distribution and selling capabilities. OTC offers readily available consumer medicine. Animal Health provides veterinary products for farm and companion animals.
OTC (over-the-counter medicines) offers products for the treatment and prevention of common medical conditions and ailments. OTC business focuses on a group of global brands in product categories that include treatments for cough/cold/respiratory (Triaminic, Otrivin, TheraFlu/NeoCitran), pain relief (Excedrin, Voltaren), digestive health (Benefiber, Prevacid24HR, Pantoloc Control), dermatology (Lamisil, Fenistil), and smoking cessation (Habitrol/Nicotinell).
Animal Health offers products and services focusing on both companion and farm animals (including cultivated fish). Key products for companion animals include Atopica (atopic dermatitis manageme! nt), Dera! maxx and Onsior (pain relief), Fortekor (heart failure in dogs, chronic renal insufficiency in cats), and Sentinel/Milbemax/Interceptor (intestinal parasite control and heartworm prevention), while farm animal products include the therapeutic anti-infective Denagard, an antimicrobial used to treat and control bacteria in swine, CLiK, an insect growth regulator used to control blowfly strike in sheep, cattle vaccines used to prevent respiratory and reproductive diseases in beef and dairy cattle, and Zolvix, a sheep drench representing the new sheep anthelmintic class. Aquaculture products include vaccines and treatments mainly used in salmon farming.
Advisors' Opinion:- [By Charles Rice, Associate Editor - November 6, 2013 Money Morning]
Novartis AG (NYSE ADR: NVS) is the largest pharmaceutical company in Russia. Its subsidiary Sandoz is one of the largest generics manufacturers in the world.
- [By Sean Williams]
So what: It's been a miserable day for Allergan, which started the day off by slightly lowering its full-year EPS forecast from a range of $4.75-$4.83 to $4.70-$4.76. To add the icing on the cake, its midday report that DARPin did show some differentiation from Novartis (NYSE: NVS ) and Roche's (NASDAQOTH: RHHBY ) Lucentis but didn't demonstrate enough to move the drug onto phase 3 trials, sent Allergan into the abyss. It probably doesn't help, either, that MAP's inhaled migraine drug Levadex, which Allergan acquired when it purchased MAP for nearly $1 billion earlier this year, also recently received its second complete response letter. Allergan just can't seem to catch a break.
- [By Brian Orelli]
APD334 is a modulator of sphingosine 1-phosphate subtype 1, or S1P1. Drugs such as Novartis' (NYSE: NVS ) Gilenya, which is in this class, are thought to work by retaining lymphocytes in the lymph nodes so they don't attack other tissue. Lowering patients' lymphocyte counts in the blood is clearly a sign APD334 is doing what it's supposed to.
Top 10 Healthcare Technology Companies To Watch In Right Now: CannaVEST Corp (CANV)
CannaVEST Corp., formerly Foreclosure Solutions, Inc., incorporated on December 9, 2010, is engaged in the business of developing, producing, marketing and selling end consumer products to the nutriceutical industry containing the hemp plant extract, Cannabidoil (CBD). The Company produces raw ingredients for neutraceutical markets. This substance can be used with foods and nutritional supplements for consumer health and wellness benefits, as well as in the pharmaceutical industry. On March 4, 2013, the Company acquired KannaLife Sciences, Inc. On December 31, 2012, the Company acquired certain assets of PhytoSPHERE Systems, LLC (PhytoSPHERE). It also secured the license to the name PhytoSPHERE and PhytoSPHERE Systems for use in the development and commercialization of hemp-based products.
The Company focuses to develop applicable raw ingredients, and provide raw ingredients for the production and development of multiple existing and developing product applications. Its focus is to produce, market and distribute hemp-based consumer products, as well as acquire existing businesses involved in the industrial hemp industries.
Advisors' Opinion:- [By John Udovich]
The Marijuana Index is Really Getting Stoned. The Marijuana Index, which is the first and only registered equity tracking index for marijuana stocks, cannabis stocks and hemp stocks,�experienced significant volume and price fluctuations throughout the month of February when is started the month at the $25 level only to close the month at $56.21 for a 125% gain as some marijuana stocks experienced all time highs. Notable gainers included Abattis Bioceuticals (OTCMKTS: ATTBF)�being up 194%, Advanced Cannabis Solutions (OTCQB: CANN) being up 132% and CannaVest (OTCMKTS: CANV) being up 116%. You can see all of the�Marijuana Index�� advancers and decliners at http://www.marijuanaindex.org.
Top 10 Healthcare Technology Companies To Watch In Right Now: Camden Property Trust (CPT)
Camden Property Trust is a real estate investment trust (REIT). The Company is engaged in the ownership, management, development, acquisition, and construction of multi-family apartment communities. As each of its communities has similar economic characteristics, residents, amenities, and services, its operations have been aggregated into one segment.
In April 2011, it sold one of its land parcels to one of the Funds. In June 2011, it sold another land parcel to the Fund. In August 2011, the Company acquired 30.1 acres of land located in Atlanta, Georgia. In December 2011, it acquired 2.2 acres of land in Glendale, California. During the year ended December 31, 2011, it sold two properties consisting of 788 units located in Dallas, Texas. During 2011, the Funds acquired 18 multifamily properties totaling 6,076 units located in the Houston, Dallas, Austin, San Antonio, Tampa and Atlanta. In January 2012, one of the Funds acquired one multifamily property consisted of 350 units located in Raleigh, North Carolina.
As of December 31, 2011, the Company owned interests in, operated, or were developing 206 multifamily properties comprising 69,794 apartment homes across the United States. Of these 206 properties, 10 properties were under development. In addition, it owns land parcels, which it focuses on developing into multifamily apartment communities.
Advisors' Opinion:- [By Michael Lewis]
Take Camden Property Trust (NYSE: CPT ) , for example. The stock is up around 16% over two years -- respectable, but incongruent with the industry trends. Since 2010, operating cash flow has increased more than 30%. The company pays a 3.5% dividend and trades at 16.5 times projected one-year earnings. For comparison, Lennar trades at 18 times earnings, while KB Homes trades at more than 20 times forward earnings.
No comments:
Post a Comment